Legal & General Group Plc Has $5.41 Million Holdings in Guardant Health, Inc. (NASDAQ:GH)

Legal & General Group Plc lessened its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 9.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 177,187 shares of the company's stock after selling 18,302 shares during the quarter. Legal & General Group Plc owned approximately 0.14% of Guardant Health worth $5,413,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of GH. Lord Abbett & CO. LLC acquired a new stake in shares of Guardant Health in the third quarter valued at about $15,624,000. Guyasuta Investment Advisors Inc. bought a new position in Guardant Health in the fourth quarter valued at approximately $206,000. Geode Capital Management LLC increased its position in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of Guardant Health during the 4th quarter worth approximately $377,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Guardant Health during the 4th quarter worth approximately $2,211,000. Institutional investors own 92.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on GH. Raymond James restated an "outperform" rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Morgan Stanley boosted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Piper Sandler raised their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Stifel Nicolaus boosted their price target on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, February 24th. Twenty research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Guardant Health presently has an average rating of "Buy" and a consensus price target of $49.00.

Guardant Health Stock Down 0.1 %

Shares of GH stock traded down $0.05 during trading hours on Friday, reaching $47.36. The company's stock had a trading volume of 375,266 shares, compared to its average volume of 2,134,313. Guardant Health, Inc. has a fifty-two week low of $16.77 and a fifty-two week high of $50.89. The company has a market capitalization of $5.84 billion, a price-to-earnings ratio of -13.31 and a beta of 1.45. The firm's 50 day simple moving average is $43.37 and its 200-day simple moving average is $37.00.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.